BSE Live
Jan 16, 16:01Prev. Close
1180.25
Open Price
1171.55
Bid Price (Qty.)
1172.30 (1)
Offer Price (Qty.)
1179.00 (1)
NSE Live
Jan 16, 15:50Prev. Close
1180.10
Open Price
1174.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1172.70 (585)
| Balance Sheet of Aurobindo Pharma (in Rs. Cr.) | Mar 05 | Mar 04 | |
| 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 25.39 | 25.38 | |
| Total Share Capital | 25.39 | 25.38 | |
| Reserves and Surplus | 763.20 | 730.99 | |
| Total Reserves and Surplus | 763.20 | 730.99 | |
| Total Shareholders Funds | 788.59 | 756.37 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 433.78 | 351.04 | |
| Deferred Tax Liabilities [Net] | 76.57 | 58.30 | |
| Other Long Term Liabilities | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 510.35 | 409.34 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 395.34 | 267.35 | |
| Trade Payables | 183.59 | 129.05 | |
| Other Current Liabilities | 11.56 | 26.04 | |
| Short Term Provisions | 10.99 | 20.25 | |
| Total Current Liabilities | 601.48 | 442.69 | |
| Total Capital And Liabilities | 1,935.42 | 1,643.40 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 578.05 | 473.00 | |
| Intangible Assets | 16.73 | 0.00 | |
| Capital Work-In-Progress | 176.50 | 111.60 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 771.28 | 584.60 | |
| Non-Current Investments | 151.27 | 148.89 | |
| Deferred Tax Assets [Net] | 20.59 | 6.19 | |
| Long Term Loans And Advances | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | |
| Total Non-Current Assets | 943.14 | 739.68 | |
| CURRENT ASSETS | |||
| Current Investments | 0.00 | 0.00 | |
| Inventories | 323.58 | 259.64 | |
| Trade Receivables | 441.38 | 456.85 | |
| Cash And Cash Equivalents | 13.80 | 37.41 | |
| Short Term Loans And Advances | 213.50 | 149.48 | |
| OtherCurrentAssets | 0.02 | 0.34 | |
| Total Current Assets | 992.28 | 903.72 | |
| Total Assets | 1,935.42 | 1,643.40 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 114.91 | 98.65 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 498.21 | 511.75 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 32.48 | 27.84 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 28.69 | 31.94 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | 554.62 | 642.04 | |
| Other Earnings | 8.10 | 2.83 | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | 17.35 | 17.35 | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | -- | -- | |
| Non-Current Investments Unquoted Book Value | 151.27 | 148.89 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- |
07.01.2026
02.01.2026
19.12.2025
15.12.2025
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL